Immix Biopharma, Inc. (NASDAQ: IMMX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 17.28% | Shs Outstand | 54.40M | Perf Week | -3.11% |
| Market Cap | 458.06M | Forward P/E | - | EPS next Y | -0.84 | Insider Trans | 0.00% | Shs Float | 43.40M | Perf Month | -18.57% |
| Enterprise Value | 368.06M | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 19.59% | Perf Quarter | -9.46% |
| Income | -29.00M | P/S | 0.00 | EPS this Y | - | Inst Trans | - | Short Ratio | 5.57 | Perf Half Y | 44.43% |
| Sales | 0.00 | P/B | 5.45 | EPS next Y | -19.11% | ROA | -36.51% | Short Interest | 8.50M | Perf YTD | 60.99% |
| Book/sh | 1.54 | P/C | 5.03 | EPS next 5Y | - | ROE | -73.23% | 52W High | 13.45 -30.64% | Perf Year | 209.56% |
| Cash/sh | 1.67 | P/FCF | - | EPS past 3/5Y | - | ROIC | -42.25% | 52W Low | 2.15 334.02% | Perf 3Y | 316.83% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 6.52% 8.20% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | -19.74% | Oper. Margin | 0.00% | ATR (14) | 0.75 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 8.76 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 41.14 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.76 | EPS Q/Q | -20.00% | SMA20 | -12.72% | Beta | 1.44 | Target Price | 17.00 |
| Payout | 0.00% | Debt/Eq | 0.01 | Sales Q/Q | - | SMA50 | -9.33% | Rel Volume | 0.92 | Prev Close | 8.42 |
| Employees | 21 | LT Debt/Eq | 0.01 | Earnings | Aug 14 | SMA200 | 13.29% | Avg Volume | 1.76M | Price | 9.33 |
| IPO Date | Dec 16, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 0.30% - | Net Debt/EBITDA | 2.26 | Volume | 1,618,136 | Change | 10.81% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| May-22-26 | Reiterated | HC Wainwright & Co. | Buy | $15 → $20 |
| Mar-27-26 | Reiterated | HC Wainwright & Co. | Buy | $12 → $15 |
| Feb-09-26 | Initiated | Mizuho | Outperform | $14 |
| Dec-09-25 | Reiterated | HC Wainwright & Co. | Buy | $7.00 → $12 |
| Jul-01-24 | Initiated | H.C | Buy | $7.00 |
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Selling, General and Administrative Excl. Other | 14 | 11 | 7 | 4 | 1 | 0 | 0 | |
| Research and Development | 16 | 11 | 9 | 4 | 0 | 0 | 1 | |
| Other Operating Expense | -3 | 1 | 0 | 0 | 0 | 0 | 0 | |
| Operating Income | -27 | -23 | -16 | -8 | -1 | 0 | -1 | |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Unusual Expense | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -2 | 1 | 1 | 0 | -23 | -1 | 0 | |
| Net Income Before Taxes | -29 | -22 | -16 | -8 | -24 | -1 | -1 | |
| Income Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Consolidated Net Income | -29 | -22 | -15 | -8 | -24 | -1 | -1 | |
| Net Income From Continuing Operations | -29 | -22 | -16 | -8 | -24 | -1 | -1 | |
| Net Income | -29 | -22 | -15 | -8 | -24 | -1 | -1 | |
| EPS (Recurring) | -0.89 | -0.76 | -0.89 | -0.59 | -6.64 | -0.15 | -0.29 | |
| EPS (Basic, Before Extraordinaries) | -0.89 | -0.76 | -0.89 | -0.59 | -6.64 | -0.15 | -0.29 | |
| EPS (Diluted) | -0.89 | -0.76 | -0.89 | -0.59 | -6.64 | -0.15 | -0.29 | |
| EBITDA | -29 | -22 | -16 | -8 | -24 | 0 | -1 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | |
| Shares Outstanding | 33 | 28 | 17 | 14 | 4 | 8 | 3 | |
| Market Capitalization | 173 | 62 | 118 | 32 | 14 | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Rachman Ilya M | CEO and Chairman | Dec 10 '25 | Buy | 6.67 | 746 | 4,976 | 1,141,683 | Dec 10 |
| Morris Gabriel S | CFO | Dec 10 '25 | Buy | 6.58 | 770 | 5,067 | 291,429 | Dec 10 |
| Morris Gabriel S | CFO | Dec 08 '25 | Option Exercise | 0.80 | 216,000 | 172,800 | 426,844 | Dec 10 |
| Rachman Ilya M | CEO and Chairman | Sep 17 '25 | Buy | 2.02 | 2,500 | 5,050 | 1,140,937 | Sep 17 |
| Morris Gabriel S | CFO | Sep 16 '25 | Buy | 1.97 | 2,600 | 5,122 | 290,659 | Sep 17 |
| Morris Gabriel S | CFO | Jun 18 '25 | Buy | 2.28 | 2,225 | 5,071 | 288,059 | Jun 20 |
| Rachman Ilya M | CEO and Chairman | Jun 18 '25 | Buy | 2.29 | 2,178 | 4,999 | 1,138,437 | Jun 20 |
| Hsu Jason | Director | Dec 23 '24 | Buy | 2.19 | 40,000 | 87,680 | 893,000 | Dec 26 |
| Hsu Jason | Director | Dec 20 '24 | Buy | 2.17 | 7,700 | 16,678 | 853,000 | Dec 26 |
| Hsu Jason | Director | Aug 22 '24 | Buy | 2.25 | 8,100 | 18,233 | 845,300 | Aug 26 |
| Hsu Jason | Director | Aug 21 '24 | Buy | 2.23 | 15,000 | 33,390 | 837,200 | Aug 26 |
| Ng Carey | Director | Aug 16 '24 | Buy | 1.86 | 10,000 | 18,600 | 20,000 | Aug 19 |
| Hsu Jason | Director | Jul 24 '24 | Buy | 2.15 | 6,000 | 12,877 | 822,200 | Jul 31 |
| Hsu Jason | Director | Jul 18 '24 | Buy | 2.07 | 3,200 | 6,639 | 816,200 | Jul 31 |
| Rachman Ilya M | CEO and Chairman | Jun 07 '24 | Buy | 2.13 | 2,600 | 5,538 | 1,136,259 | Jun 10 |